Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.52 |
| ▸ | APLNR | P35414 | 2/20 | 0.52 |
| ▸ | CALCR | P30988 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.46 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454361 | 0.89 | REN (0.51) | F2APLNROPRM1OPRD1 | |
| SCHEMBL30233449 | 0.86 | CALCR (0.58) | F2APLNRCALCROPRM1OPRD1 | |
| SCHEMBL30266728 | 0.86 | F2 (0.60) | F2APLNRCALCROPRM1OPRD1 | |
| SCHEMBL30512510 | 0.86 | CALCR (0.51) | F2APLNRCALCRNMUR2NMUR1 | |
| SCHEMBL29842938 | 0.85 | CALCR (0.58) | F2APLNRCALCROPRM1OPRD1 | |
| SCHEMBL30233337 | 0.84 | CALCR (0.60) | F2APLNRCALCROPRM1OPRD1 | |
| SCHEMBL38662213 | 0.84 | CALCR (0.60) | F2APLNRCALCRC5AR1 | |
| SCHEMBL30974276 | 0.83 | F2 (0.61) | F2APLNRCALCROPRM1OPRD1 | |
| SCHEMBL29856457 | 0.83 | CALCR (0.57) | F2APLNRCALCRC5AR1 | |
| SCHEMBL30455799 | 0.83 | APLNR (0.47) | F2APLNRCALCRC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | claimed |
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (OR) | 2024-10-17 | — | — | US | disclosed |
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | ARGLU1, TPX2, RXFP1 | F2 2604/4885APLNR 122/4885CALCR 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.